Latin America Pharmaceutical Contract Manufacturing Market: Market Size & Forecast 2026

Brazil, Mexico, and Argentina collectively form the manufacturing backbone of Latin America's pharmaceutical contract manufacturing sector, with established capabilities spanning active pharmaceutical ingredients, generic drugs, and increasingly, biologics and biosimilars. The region's contract manufacturers serve both domestic markets and international clients seeking to diversify supply chains away from traditional manufacturing hubs. Regulatory frameworks administered by agencies such as Brazil's ANVISA and supported by PAHO have progressively aligned with international standards, facilitating both regional integration and export-oriented production.

• •Brazil commands the largest domestic manufacturing capacity in the region, with significant initiatives to expand local active pharmaceutical ingredient production and reduce import dependency
• •The contract manufacturing ecosystem includes both regional specialists and global pharmaceutical companies operating local production facilities
• •Regulatory harmonization through PAHO-supported initiatives has streamlined approval processes and quality standards across multiple Latin American markets

Nearshoring trends accelerated by global supply chain disruptions have positioned Latin America as an attractive alternative manufacturing base for North American and European pharmaceutical companies seeking geographic diversification and supply chain resilience. The region's growing domestic pharmaceutical markets, driven by expanding healthcare access and aging populations, create sustained demand for contract manufacturing services. Cost competitiveness relative to North America and Europe, combined with improving infrastructure and a skilled scientific workforce, further strengthens the region's appeal to global clients.

• •The biosimilar and generic drug segment represents one of the fastest-growing components, driven by patent expiries and cost-containment pressures across global healthcare systems
• •Continuous manufacturing technologies are being adopted across regional facilities, enabling more efficient production and improved cost structures for contract manufacturers
• •Government initiatives in Brazil and Mexico to incentivize local pharmaceutical production have spurred significant investment in contract manufacturing infrastructure and capacity

The market spans active pharmaceutical ingredient manufacturing, finished dosage form production, and increasingly sophisticated biologics and biosimilar development services across multiple therapeutic categories. Brazil leads in overall manufacturing volume, with particular strength in generic pharmaceuticals and growing API production capacity, while Mexico leverages its proximity to the United States for nearshoring-oriented contract manufacturing. Argentina maintains notable capabilities in biotechnology and biopharmaceutical production, supported by a well-established scientific research infrastructure.

• •Brazil's pharmaceutical manufacturing sector has received substantial government support for API localization, with strategic programs aimed at reducing reliance on imported active ingredients
• •Mexico's geographic proximity to the U.S. market and participation in USMCA trade agreements make it particularly attractive for North American pharmaceutical companies seeking nearshoring partners
• •Argentina hosts established biotechnology clusters and maintains a skilled scientific workforce, supporting its position in biosimilar and specialty pharmaceutical manufacturing

What are the recent trends and outlook?

The Latin American pharmaceutical contract manufacturing sector is expected to sustain its growth trajectory through the remainder of the decade, supported by ongoing nearshoring momentum and continued investment in manufacturing infrastructure and technology upgrades. Advances in continuous bioprocessing and digital manufacturing technologies are enabling regional CDMOs to offer more sophisticated development and production services, particularly for biologics and biosimilars. Regulatory convergence efforts led by PAHO and national agencies such as ANVISA are expected to further reduce barriers to cross-border pharmaceutical trade and manufacturing collaboration throughout the region.

• •The adoption of continuous manufacturing and single-use bioprocessing technologies is enabling Latin American CDMOs to reduce production costs and improve flexibility for both regional and international clients
• •Expansion of biosimilar manufacturing capabilities is anticipated across Brazil, Mexico, and Argentina as patent protections expire on high-value biologic drugs, creating significant new contract manufacturing opportunities
• •Regulatory harmonization initiatives and strengthened pharmacovigilance frameworks are expected to facilitate greater integration of Latin American manufacturing into global pharmaceutical supply chains